AP SA01
Alternative Names: AB SA01; AmpliPhage-002; AP-SA01Latest Information Update: 05 Apr 2021
At a glance
- Originator Biocontrol
- Developer Armata Pharmaceuticals; United States Army Medical Research and Materiel Command; University of Adelaide; Westmead Institute for Medical Research
- Class Antibacterials; Bacteriophages
- Mechanism of Action Bacterial DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 22 Apr 2020 Discontinued - Clinical-Phase-Unknown for Staphylococcal infections (Treatment-resistant) in USA, Australia (IV)
- 22 Apr 2020 Discontinued - Phase-I for Staphylococcal infections (In volunteers) in USA (Topical)
- 22 Apr 2020 Discontinued - Phase-I for Staphylococcal infections (Treatment-resistant) in Australia (Intranasal)